{"id":"W4410950112","doi":"10.1080/14796694.2025.2502318","title":"rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Enzalutamide; Medicine; Cabazitaxel; Prostate cancer; Androgen receptor; Abiraterone acetate; Oncology; Internal medicine; Docetaxel; Randomized controlled trial; Clinical endpoint; Clinical trial; Androgen deprivation therapy; Pharmacology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002645212,0.001703757,0.001866667,0.0003941895,0.0004473733,0.00119562,0.001081398,0.001697711,0.007077096],"category_scores_gemma":[0.001889514,0.0005249573,0.001399116,0.000436346,0.001544826,0.001657259,0.000477732,0.003584861,0.0009652462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008675354,"about_ca_system_score_gemma":0.001352821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007189302,"about_ca_topic_score_gemma":0.002225428,"domain_scores_codex":[0.9992142,0.0004664201,0.00003137711,0.0001112592,0.000055104,0.0001216829],"domain_scores_gemma":[0.9990079,0.0002712605,0.0002264809,0.00008431217,0.00004409163,0.0003660011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9586148,0.01194186,0.000754017,0.0003219851,0.000428786,0.0000478395,0.00008502798,0.000611811,0.003685429,0.0003517903,0.001662383,0.02149433],"study_design_scores_gemma":[0.9041436,0.09264731,0.0009773594,0.00001585042,0.0001421385,0.00003766188,0.00002987577,0.0004766925,0.0003938404,0.0003143742,0.0008077832,0.00001349051],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833974,0.002912981,0.0009440464,0.001390851,0.0005917628,0.005632916,0.001296189,0.0002048188,0.003629025],"genre_scores_gemma":[0.9840894,0.001588626,0.002017644,0.001616681,0.0005137798,0.004972489,0.001274935,0.00004745389,0.003878938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007077096,"threshold_uncertainty_score":0.02367526,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01713607726596698,"score_gpt":0.3317622043259618,"score_spread":0.3146261270599948,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}